Better breast cancer drug in sight for Genentech
Better breast cancer drug in sight for Genentech
Genentech Inc. broke ground with a targeted antibody drug for breast cancer in the late 1990s, and now it is showing another sign it may have surpassed the original.
Read more on Boston Globe
FDA denies accelerated approval for ImmunoGen, Genentech potential breast cancer treatment
FDA denies accelerated approval for ImmunoGen, Genentech potential breast cancer treatment
WALTHAM, Mass. – Federal regulators have ruled that a potential breast cancer treatment from ImmunoGen failed to meet the standard for accelerated approval, the company said Friday.
Read more on Minneapolis-St. Paul Star Tribune
Categories: Breast Cancer Treatment Tags: Accelerated, Approval, breast, cancer, Denies, Genentech, ImmunoGen, Potential, Treatment
Genentech Provides Update From Avastin FDA Advisory Committee Meeting
Genentech Provides Update From Avastin FDA Advisory Committee Meeting
Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one that use of Avastin® (bevacizumab) in combination with paclitaxel for previously untreated (first-line) advanced HER2-negative breast cancer be removed from Avastin’s U.S. label. The committee’s vote does …
Read more on Medical News Today
Categories: Metastatic Breast Cancer Tags: Advisory, Avastin, Committee, From, Genentech, Meeting, Provides, Update
Genentech disappointed with FDA ODAC’s recommendation against Avastin
Genentech disappointed with FDA ODAC’s recommendation against Avastin
Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one that use of Avastin® (bevacizumab) in combination with paclitaxel for previously untreated (first-line) advanced HER2-negative breast cancer be removed from Avastin’s U.S. label.
Read more on News-Medical-Net
Categories: High Risk Breast Cancer Tags: against, Avastin, disappointed, Genentech, ODAC's, Recommendation
Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer
Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer
Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening …
Read more on News-Medical-Net
Categories: Breast Cancer Chemotherapy Tags: advanced, Avastin, cancer, From, Genentech, Ovarian, Phase, Reports, Results, Study, women
Genentech to present new data for targeted cancer medicines at 46th ASCO
Genentech to present new data for targeted cancer medicines at 46th ASCO
Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche’s cancer medicines and investigational agents across 30 …
Read more on News-Medical-Net